FORMULATION AND EVALUATION OF CONTROLLED RELEASED AT ORVASTATIN INSITUGELS FOR THE TREATMENT OF PERIODONTAL DISEASES
DOI:
https://doi.org/10.48047/Keywords:
Atorvastatin, Periodontal diseases,Bonetissueregeneration,In situgels,PLGA,ControlledreleaseAbstract
Thetreatmentforperiodontaldiseasesincludessystemictreatmentwithantibiotics.Localadministrationusing intrapocketdrugdeliverywithsolgeltechniquesisrecentlyevaluated.Bonetissueregenerationisanimportantfactortobeconsider
edfortreatmentassociatedwithchronicperiodontitis.Thisresearchworkrevealstheformulationandinvitroevaluationofperi
odontalpocketeddrugdeliveryofatorvastatin,abonetissueregenerator,usingsol-geltechnique.Atotalof
sixformulationswerepreparedwithpolylacticcoglycolicacid(PLGA)andsolventconcentrationskeepingthedrugconcentr
ation50mgthroughoutthestudy.ThedrugexcipientcompatibilitieswereperformedusingIRspectroscopy.Formulationstud
iesweredonebyconsideringspreadabilitystudies,viscosities,solgeltransitiontemperaturesandinvitrodrugrelease.Noabno
rmalorshiftinpeakswereidentifiedandsupportstheselectionofpolymerforfurtherformulationstudies.Itwasidentifiedthatt
hereleaseratewasdirectlyproportionaltodrugconcentrationindicatingthefirstorderreleasekineticsof
atorvastatin.Also,basedontheHiguchiandKorsmeyerpeppasmodels,itcouldbeinterpretedthatthepreparedformulationsfo
llowNonFickiandiffusiontransportmechanisms.Itwasidentifiedthatalltheformulationsshowedgoodphysicalappearance
byformingclearsolutionswhenprepared. The pHofalltheformulationswereinbetween5.9to6.1indicating that they were
slightlyacidictoneutraland could beadministeredtotheoralcavity. Basedongellingproperties, spreadability and
syringeability andviscosityprofiles, the formulationF4showed betterprofilecomparedtotherestoftheformulations.In
vitrodrugreleasestudiesrevealedthattheformulationsfollowedfirstorderkineticswithnonFickiandiffusionmechanism.Su
stainedandprolongedrelease was achievedforalltheformulations.FormulationsF5 and F6 had prolonged drug
releaseofupto50days.However,consideringallthephysicochemicalparametersandinvitroreleaseprofilesintoaccounttheo
ptimizedformulations was considered to be F4.Thisformulationisfurtherproposedto be considered forin vivostudies.